BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yu KH, Ricigliano M, Hidalgo M, Abou-Alfa GK, Lowery MA, Saltz LB, Crotty JF, Gary K, Cooper B, Lapidus R. Pharmacogenomic modeling of circulating tumor and invasive cells for prediction of chemotherapy response and resistance in pancreatic cancer. Clin Cancer Res. 2014;20:5281-5289. [PMID: 25107917 DOI: 10.1158/1078-0432.ccr-14-0531] [Cited by in Crossref: 37] [Cited by in F6Publishing: 18] [Article Influence: 4.6] [Reference Citation Analysis]
Number Citing Articles
1 Mertens F, Johansson B, Fioretos T, Mitelman F. The emerging complexity of gene fusions in cancer. Nat Rev Cancer 2015;15:371-81. [PMID: 25998716 DOI: 10.1038/nrc3947] [Cited by in Crossref: 348] [Cited by in F6Publishing: 312] [Article Influence: 49.7] [Reference Citation Analysis]
2 Su PJ, Wu MH, Wang HM, Lee CL, Huang WK, Wu CE, Chang HK, Chao YK, Tseng CK, Chiu TK. Circulating Tumour Cells as an Independent Prognostic Factor in Patients with Advanced Oesophageal Squamous Cell Carcinoma Undergoing Chemoradiotherapy. Sci Rep. 2016;6:31423. [PMID: 27530152 DOI: 10.1038/srep31423] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
3 Dotan E, Alpaugh RK, Ruth K, Negin BP, Denlinger CS, Hall MJ, Astsaturov I, McAleer C, Fittipaldi P, Thrash-Bingham C, Meropol NJ, Cohen SJ. Prognostic Significance of MUC-1 in Circulating Tumor Cells in Patients With Metastatic Pancreatic Adenocarcinoma. Pancreas 2016;45:1131-5. [PMID: 26967453 DOI: 10.1097/MPA.0000000000000619] [Cited by in Crossref: 31] [Cited by in F6Publishing: 16] [Article Influence: 7.8] [Reference Citation Analysis]
4 Lowery MA, Ptashkin R, Jordan E, Berger MF, Zehir A, Capanu M, Kemeny NE, O'Reilly EM, El-Dika I, Jarnagin WR, Harding JJ, D'Angelica MI, Cercek A, Hechtman JF, Solit DB, Schultz N, Hyman DM, Klimstra DS, Saltz LB, Abou-Alfa GK. Comprehensive Molecular Profiling of Intrahepatic and Extrahepatic Cholangiocarcinomas: Potential Targets for Intervention. Clin Cancer Res. 2018;24:4154-4161. [PMID: 29848569 DOI: 10.1158/1078-0432.ccr-18-0078] [Cited by in Crossref: 117] [Cited by in F6Publishing: 75] [Article Influence: 29.3] [Reference Citation Analysis]
5 Lee RC, Kanhere H, Trochsler M, Broadbridge V, Maddern G, Price TJ. Pancreatic, periampullary and biliary cancer with liver metastases: Should we consider resection in selected cases? World J Gastrointest Oncol 2018; 10(8): 211-220 [PMID: 30147847 DOI: 10.4251/wjgo.v10.i8.211] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
6 Xiong Y, Huang BY, Yin JY. Pharmacogenomics of platinum-based chemotherapy in non-small cell lung cancer: focusing on DNA repair systems. Med Oncol 2017;34:48. [PMID: 28215024 DOI: 10.1007/s12032-017-0905-6] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 6.2] [Reference Citation Analysis]
7 Tieng FYF, Baharudin R, Abu N, Mohd Yunos RI, Lee LH, Ab Mutalib NS. Single Cell Transcriptome in Colorectal Cancer-Current Updates on Its Application in Metastasis, Chemoresistance and the Roles of Circulating Tumor Cells. Front Pharmacol 2020;11:135. [PMID: 32174835 DOI: 10.3389/fphar.2020.00135] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 5.5] [Reference Citation Analysis]
8 Dong H, Tulley S, Zhao Q, Cho L, Chen D, Pearl ML, Chen WT. The propensity of invasive circulating tumor cells (iCTCs) in metastatic progression and therapeutic responsiveness. Cancer Med 2019;8:3864-74. [PMID: 31115187 DOI: 10.1002/cam4.2218] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
9 Varghese AM, Lowery MA, Yu KH, O'Reilly EM. Current management and future directions in metastatic pancreatic adenocarcinoma. Cancer 2016;122:3765-75. [PMID: 27649047 DOI: 10.1002/cncr.30342] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
10 Yadav DK, Bai X, Yadav RK, Singh A, Li G, Ma T, Chen W, Liang T. Liquid biopsy in pancreatic cancer: the beginning of a new era. Oncotarget 2018;9:26900-33. [PMID: 29928492 DOI: 10.18632/oncotarget.24809] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 7.0] [Reference Citation Analysis]
11 Ramanathan RK, Weiss GJ, Posner RG, Rajeshkumar NV, Jameson G, Aziz M, Hoering A, Bolejack V, Maitra A, Fulk M, Stites EC, Hlavacek WS, Gatalica Z, Xiu J, Hidalgo M, Von Hoff DD, Barrett MT. A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients. J Gastrointest Oncol 2017;8:925-35. [PMID: 29299351 DOI: 10.21037/jgo.2017.09.05] [Reference Citation Analysis]
12 Goel G, Sun W. Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future. J Hematol Oncol. 2015;8:44. [PMID: 25935754 DOI: 10.1186/s13045-015-0141-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
13 Yu KH, Ricigliano M, McCarthy B, Chou JF, Capanu M, Cooper B, Bartlett A, Covington C, Lowery MA, O'Reilly EM. Circulating Tumor and Invasive Cell Gene Expression Profile Predicts Treatment Response and Survival in Pancreatic Adenocarcinoma. Cancers (Basel) 2018;10:E467. [PMID: 30477242 DOI: 10.3390/cancers10120467] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
14 Lee CH, Hsieh JC, Wu TM, Yeh TS, Wang HM, Lin YC, Chen JS, Lee CL, Huang WK, Hung TM, Yen TT, Chan SC, Chou WC, Kuan FC, Hu CC, Chang PH. Baseline circulating stem-like cells predict survival in patients with metastatic breast Cancer. BMC Cancer 2019;19:1167. [PMID: 31791269 DOI: 10.1186/s12885-019-6370-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
15 Krantz BA, O'Reilly EM. Biomarker-Based Therapy in Pancreatic Ductal Adenocarcinoma: An Emerging Reality? Clin Cancer Res 2018;24:2241-50. [PMID: 29269376 DOI: 10.1158/1078-0432.CCR-16-3169] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
16 Heredia-Soto V, Rodríguez-Salas N, Feliu J. Liquid Biopsy in Pancreatic Cancer: Are We Ready to Apply It in the Clinical Practice? Cancers (Basel) 2021;13:1986. [PMID: 33924143 DOI: 10.3390/cancers13081986] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
17 Martini V, Timme-Bronsert S, Fichtner-Feigl S, Hoeppner J, Kulemann B. Circulating Tumor Cells in Pancreatic Cancer: Current Perspectives. Cancers (Basel) 2019;11:E1659. [PMID: 31717773 DOI: 10.3390/cancers11111659] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
18 Genovesi LA, Millar A, Tolson E, Singleton M, Hassall E, Kojic M, Brighi C, Girard E, Andradas C, Kuchibhotla M, Bhuva DD, Endersby R, Gottardo NG, Bernard A, Adolphe C, Olson JM, Taylor MD, Davis MJ, Wainwright BJ. Systems pharmacogenomics identifies novel targets and clinically actionable therapeutics for medulloblastoma. Genome Med 2021;13:103. [PMID: 34154646 DOI: 10.1186/s13073-021-00920-z] [Reference Citation Analysis]